Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met
Authors:
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 680, 108239
Abstract
No abstract availableKeywords
Funding Information
- Program for Liaoning Innovative Talents in University
- Liaoning Revitalization Talents Program
- National Natural Science Foundation of China (81301901)
- National Natural Science Foundation of China (HL)
This publication has 32 references indexed in Scilit:
- The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypesAnti-Cancer Drugs, 2014
- Genome-wide survey of recurrent HBV integration in hepatocellular carcinomaNature Genetics, 2012
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinomaInternational Journal of Clinical Oncology, 2012
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinomaHepatology, 2011
- Role of Cyclin D1 as a Mediator of c-Met– and β-Catenin–Induced HepatocarcinogenesisCancer Research, 2008
- Regulation of MAPKs by growth factors and receptor tyrosine kinasesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Invasive growth: a MET-driven genetic programme for cancer and stem cellsNature Reviews Cancer, 2006
- Dynasore, a Cell-Permeable Inhibitor of DynaminDevelopmental Cell, 2006
- Cyclin E in normal and neoplastic cell cyclesOncogene, 2005
- A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with RapamycinClinical Cancer Research, 2005